Showing results (2121-2130 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|August 25, 2000
Development of multidrug-resistance convertors: sense or nonsense?L van Zuylen, K Nooter, A Sparreboom, et al.Investigational New Drugs|August 25, 2000
The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug deliveryH A Bardelmeijer, O van Tellingen, J H Schellens, et al.Investigational New Drugs|August 25, 2000
Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, M Mazumdar, et al.Investigational New Drugs|August 25, 2000
Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumorsJ Vuky, J McCaffrey, M Ginsberg, et al.Investigational New Drugs|August 25, 2000
A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413)J S Macdonald, J L Jacobson, M Modiano, et al.Investigational New Drugs|August 25, 2000
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumorsJ T Hartmann, L M Fels, S Knop, et al.Investigational New Drugs|June 1, 2000
Advanced non-small cell lung carcinoma: the emerging role of docetaxelC J LangerInvestigational New Drugs|June 1, 2000
Gemcitabine in non-small cell lung cancer (NSCLC)C Manegold, P Zatloukal, K Krejcy, et al.Investigational New Drugs|June 1, 2000
Current approaches and future strategies for pancreatic carcinomaR A Wolff, P Chiao, R Lenzi, et al.Investigational New Drugs|June 1, 2000
Promising approaches in acute leukemiaJ Cortes, H M KantarjianPageof 372